Doctor profile · Federal record
Dr. Michael Jaworski, M.D.
Internal Medicine Physician (CMS: Rheumatology) · Philadelphia, PA
- NPI 1013035492
- Accepts Medicare
- MIPS 98.5 / 100 · 2023
- 23 yrs in practice
- Male
- Solo practice
- No sanctions
Practice & contact
- Primary practice
-
1316 W Ontario St Rm 815
Philadelphia, PA 191405220
(215) 707-3635
Credentials & registration
- NPI registered
- March 2007 — 19 yrs on file
- Profile last updated
- July 8, 2007
- Year of graduation
- 2003 — 23 yrs since
- Specialty taxonomy
- 207R00000X — NUCC code
- State license (1)
- Pennsylvania #MD429299
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1013035492. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
74,681
Distinct HCPCS
10
Medicare allowed
$2,625,405
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0897 |
Injection, denosumab, 1 mg | 27,540 | 300 | $23 | |
J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 24,735 | 61 | $42 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 7,700 | 17 | $13 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 5,827 | 32 | $31 | |
J9312 |
Injection, rituximab, 10 mg | 2,740 | 23 | $79 | |
Q5115 |
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 1,950 | 20 | $48 | |
Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 1,150 | 17 | $45 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 793 | 455 | $135 | |
96401 |
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 774 | 323 | $79 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 619 | 151 | $140 |
In context: peer comparison
Among 390 peers in this city , average services per provider: 132. This provider delivers 566× the peer median.Open Payments
Industry payments received
All-time total
$4,313
Transactions
208
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Amgen Inc. | 53 | $1,028.62 | |
| UCB, Inc. | 18 | $546.98 | |
| AstraZeneca Pharmaceuticals LP | 19 | $409.48 | |
| Janssen Biotech, Inc. | 15 | $394.14 | |
| ABBVIE INC. | 23 | $387.55 | |
| Novartis Pharmaceuticals Corporation | 19 | $225.95 | |
| E.R. Squibb & Sons, L.L.C. | 14 | $193.27 | |
| GlaxoSmithKline, LLC. | 7 | $168.43 | |
| Fresenius Kabi USA, LLC | 10 | $166.55 | |
| PFIZER INC. | 15 | $138.13 | |
| Mallinckrodt Hospital Products Inc. | 4 | $107.61 | |
| Organon Llc | 3 | $73.21 | |
| Radius Health, Inc. | 2 | $69.54 | |
| DePuy Synthes Sales Inc. | 3 | $60.44 | |
| Lilly USA, LLC | 3 | $52.65 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,410
Patients
377
Total drug cost
$667,814
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Prednisone | Generic | 380 | 106 | $5,871 |
| Methotrexate (Methotrexate Sodium) | Brand | 277 | 75 | $10,942 |
| Alendronate Sodium | Generic | 120 | 44 | $1,387 |
| Allopurinol | Generic | 103 | 30 | $1,669 |
| Celecoxib | Generic | 84 | 25 | $2,688 |
| Gabapentin | Generic | 75 | 16 | $1,359 |
| Hydroxychloroquine Sulfate | Generic | 69 | 20 | $5,461 |
| Tramadol Hcl | Generic | 55 | 18 | $629 |
| Methylprednisolone | Generic | 46 | 19 | $1,112 |
| Duloxetine Hcl | Generic | 45 | 12 | $2,294 |
Hospital affiliations
Frequently asked questions
What is Dr. Michael Jaworski's medical specialty?
Dr. Michael Jaworski practices Internal Medicine Physician in Philadelphia, PA.
Where does Dr. Michael Jaworski practice?
Dr. Michael Jaworski practices at 1316 W Ontario St Rm 815, Philadelphia, PA 191405220. Office phone: 2157073635.
What is Dr. Michael Jaworski's NPI?
Dr. Michael Jaworski's National Provider Identifier (NPI) is 1013035492, issued by NPPES.
Does Dr. Michael Jaworski accept Medicare assignment?
Yes. Dr. Michael Jaworski accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Michael Jaworski commonly perform?
Top Medicare-reported procedures in 2023: Injection, denosumab, 1 mg (HCPCS J0897); Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0129); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602). Source: CMS Medicare Physician & Other Practitioners file.